Skip to main content
SpringerLink
Log in

Ocular Paraneoplastic Diseases

  • Chapter
  • First Online:
Clinical Ophthalmic Oncology

Abstract

Paraneoplastic disorders are defined as syndromes in which the affected end organ is not a direct consequence of the mass or of distant metastasis. Instead, autoimmune response to the primary tumor causes end organ disorder and dysfunction. The temporal relationship of paraneoplastic illnesses can occur before, at the time of diagnosis, or after the identification of the primary malignancy, and in rare cases the primary malignancy may never be discovered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81(5):606–13.

    PubMed  CAS  Google Scholar 

  2. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48(1):12–38.

    Article  PubMed  Google Scholar 

  3. Chang PY, Yang CH, Yang CM. Cancer-associated retinopathy in a patient with hepatocellular carcinoma: case report and literature review. Retina. 2005;25(8):1093–6.

    Article  PubMed  Google Scholar 

  4. Katsuta H, Okada M, Nakauchi T, et al. Cancer-associated retinopathy associated with invasive thymoma. Am J Ophthalmol. 2002;134(3):383–9.

    Article  PubMed  Google Scholar 

  5. Tanaka A, Takase H, Adamus G, Mochizuki M. Cancer-associated retinopathy caused by benign thymoma. Br J Ophthalmol. 2010;94(4):526–8.

    Article  PubMed  Google Scholar 

  6. Hayashi M, Hatsukawa Y, Yasui M, et al. Cancer-associated retinopathy in a child with Langerhans cell histiocytosis. Jpn J Ophthalmol. 2007;51(5):393–6.

    Article  PubMed  CAS  Google Scholar 

  7. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev. 2009;8(5):410–4.

    Article  PubMed  CAS  Google Scholar 

  8. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. Arch Ophthalmol. 1987;105(3):372–5.

    Article  PubMed  CAS  Google Scholar 

  9. Thirkill CE, Tait RC, Tyler NK, et al. The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci. 1992;33(10):2768–72.

    PubMed  CAS  Google Scholar 

  10. Shildkrot Y, Sobrin L, Gragoudas ES. Cancer-associated retinopathy: update on pathogenesis and therapy. Semin Ophthalmol. 2011;26(4–5):321–8.

    Article  PubMed  Google Scholar 

  11. Adamus G, Aptsiauri N, Guy J, et al. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol. 1996;78(2):120–9.

    Article  PubMed  CAS  Google Scholar 

  12. Maeda A, Ohguro H, Maeda T, et al. Aberrant expression of photoreceptor-specific calcium-binding protein (recoverin) in cancer cell lines. Cancer Res. 2000;60(7):1914–20.

    PubMed  CAS  Google Scholar 

  13. Bazhin AV, Savchenko MS, Shifrina ON, et al. Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors. Lung Cancer. 2004;44(2):193–8.

    Article  PubMed  Google Scholar 

  14. Savchenko MS, Goncharskaia MA, Skorikova EE, et al. Autoantibodies against the Ca(2+)-binding protein recoverin in blood sera of patients with various oncological diseases. Oncol Lett. 2012;3(2):377–82.

    PubMed  CAS  Google Scholar 

  15. Adamus G, Ortega H, Witkowska D, Polans A. Recoverin: a potent uveitogen for the induction of photoreceptor degeneration in Lewis rats. Exp Eye Res. 1994;59(4):447–55.

    Article  PubMed  CAS  Google Scholar 

  16. Ohguro H, Ogawa K, Maeda T, et al. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci. 1999;40(13):3160–7.

    PubMed  CAS  Google Scholar 

  17. Kim JH, Kim DH, Park WY, et al. Intravenously administered anti-recoverin antibody alone does not pass through the blood-retinal barrier. Korean J Ophthalmol. 2011;25(3):189–95.

    Article  PubMed  CAS  Google Scholar 

  18. Cao R, Cao Y. Cancer-associated retinopathy: a new mechanistic insight on vascular remodeling. Cell Cycle. 2010;9(10):1882–5.

    Article  PubMed  CAS  Google Scholar 

  19. Maeda A, Maeda T, Liang Y, et al. Effects of cytotoxic T lymphocyte antigen 4 (CTLA4) signaling and locally applied steroid on retinal dysfunction by recoverin, cancer-associated retinopathy antigen. Mol Vis. 2006;12:885–91.

    PubMed  CAS  Google Scholar 

  20. Ohguro H, Rudnicka-Nawrot M, Buczylko J, et al. Structural and enzymatic aspects of rhodopsin phosphorylation. J Biol Chem. 1996;271(9):5215–24.

    Article  PubMed  CAS  Google Scholar 

  21. Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol. 2002;132(1–2):72–82.

    Article  PubMed  CAS  Google Scholar 

  22. Adamus G, Webb S, Shiraga S, Duvoisin RM. Anti-recoverin antibodies induce an increase in intracellular calcium, leading to apoptosis in retinal cells. J Autoimmun. 2006;26(2):146–53.

    Article  PubMed  CAS  Google Scholar 

  23. Weleber RG, Watzke RC, Shults WT, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol. 2005;139(5):780–94.

    Article  PubMed  CAS  Google Scholar 

  24. Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1997;38(2):283–91.

    PubMed  CAS  Google Scholar 

  25. Ohguro H, Yokoi Y, Ohguro I, et al. Clinical and immunologic aspects of cancer-associated retinopathy. Am J Ophthalmol. 2004;137(6):1117–9.

    Article  PubMed  Google Scholar 

  26. Scholl HP, Zrenner E. Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol. 2000;45(1):29–47.

    Article  PubMed  CAS  Google Scholar 

  27. Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol. 2004;4:5.

    Article  PubMed  Google Scholar 

  28. Heckenlively JR, Fawzi AA, Oversier J, et al. Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthalmol. 2000;118(11):1525–33.

    Article  PubMed  CAS  Google Scholar 

  29. Masaoka N, Emoto Y, Sasaoka A, et al. Fluorescein angiographic findings in a case of cancer-associated retinopathy. Retina. 1999;19(5):462–4.

    Article  PubMed  CAS  Google Scholar 

  30. Mohamed Q, Harper CA. Acute optical coherence tomographic findings in cancer-associated retinopathy. Arch Ophthalmol. 2007;125(8):1132–3.

    Article  PubMed  Google Scholar 

  31. Abazari A, Allam SS, Adamus G, Ghazi NG. Optical coherence tomography findings in autoimmune retinopathy. Am J Ophthalmol. 2012;153(4):750–6, 6 e1.

    Article  PubMed  Google Scholar 

  32. Keltner JL, Thirkill CE, Tyler NK, Roth AM. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol. 1992;110(1):48–53.

    Article  PubMed  CAS  Google Scholar 

  33. Ferreyra HA, Jayasundera T, Khan NW, et al. Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol. 2009;127(4):390–7.

    Article  PubMed  CAS  Google Scholar 

  34. Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol. 1999;117(4):471–7.

    Article  PubMed  CAS  Google Scholar 

  35. Espandar L, O’Brien S, Thirkill C, et al. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol. 2007;83(3):295–302.

    Article  PubMed  CAS  Google Scholar 

  36. Mahdi N, Faia LJ, Goodwin J, et al. A case of autoimmune retinopathy associated with thyroid carcinoma. Ocul Immunol Inflamm. 2010;18(4):322–3.

    Article  PubMed  Google Scholar 

  37. Murphy MA, Thirkill CE, Hart Jr WM. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol. 1997;17(2):77–83.

    Article  PubMed  CAS  Google Scholar 

  38. Ohguro H, Ogawa K, Maeda T, et al. Retinal dysfunction in cancer-associated retinopathy is improved by Ca(2+) antagonist administration and dark adaptation. Invest Ophthalmol Vis Sci. 2001;42(11):2589–95.

    PubMed  CAS  Google Scholar 

  39. Huynh N, Shildkrot Y, Lobo AM, Sobrin L. Intravitreal triamcinolone for cancer-associated retinopathy refractory to systemic therapy. J Ophthalmic Inflamm Infect. 2012;2(3):169–71.

    Article  PubMed  Google Scholar 

  40. Gass JD. Acute Vogt-Koyanagi-Harada-like syndrome occurring in a patient with metastatic cutaneous melanoma. In: Saari KM, editor. Uveitis update: proceedings of the First International Symposium on Uveitis held in Hanasaari, Espoo, Finland 1984. New York: Excerpta Medica; 1984. p. 407–8.

    Google Scholar 

  41. Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol. 1988;106(3):307–11.

    Article  PubMed  CAS  Google Scholar 

  42. Milam AH, Saari JC, Jacobson SG, et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34(1):91–100.

    PubMed  CAS  Google Scholar 

  43. Hartmann TB, Bazhin AV, Schadendorf D, Eichmuller SB. SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int J Cancer. 2005;114(1):88–93.

    Article  PubMed  CAS  Google Scholar 

  44. Lu Y, Jia L, He S, et al. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol. 2009;127(12):1572–80.

    Article  PubMed  CAS  Google Scholar 

  45. Dhingra A, Fina ME, Neinstein A, et al. Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells. J Neurosci. 2011;31(11):3962–7.

    Article  PubMed  CAS  Google Scholar 

  46. Koreen L, He SX, Johnson MW, et al. Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis. Arch Ophthalmol. 2011;129(1):23–9.

    Article  PubMed  CAS  Google Scholar 

  47. Khurana RN, Wieland MR, Boldrey EE, et al. Vitelliform retinopathy in metastatic cutaneous melanoma with choroidal involvement. Arch Ophthalmol. 2011;129(11):1498–9.

    Article  PubMed  Google Scholar 

  48. Kim RY, Retsas S, Fitzke FW, et al. Cutaneous melanoma-associated retinopathy. Ophthalmology. 1994;101(11):1837–43.

    PubMed  CAS  Google Scholar 

  49. Aronow ME, Adamus G, Abu-Asab M, et al. Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature. Surv Ophthalmol. 2012;57(6):558–64.

    Article  PubMed  Google Scholar 

  50. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001;21(3):173–87.

    Article  PubMed  CAS  Google Scholar 

  51. Pfohler C, Haus A, Palmowski A, et al. Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma. Br J Dermatol. 2003;149(1):74–8.

    Article  PubMed  CAS  Google Scholar 

  52. Borkowski LM, Grover S, Fishman GA, Jampol LM. Retinal findings in melanoma-associated retinopathy. Am J Ophthalmol. 2001;132(2):273–5.

    Article  PubMed  CAS  Google Scholar 

  53. Al-Dahmash SA, Shields CL, Bianciotto CG, et al. Acute exudative paraneoplastic polymorphous vitelliform maculopathy in five cases. Ophthalmic Surg Lasers Imaging. 2012;43(5):366–73.

    Article  PubMed  Google Scholar 

  54. Ripps H, Carr RE, Siegel IM, Greenstein VC. Functional abnormalities in vincristine-induced night blindness. Invest Ophthalmol Vis Sci. 1984;25(7):787–94.

    PubMed  CAS  Google Scholar 

  55. Monzon JG, Hammad N, Stevens SD, Dancey J. Retinopathy associated with adjuvant high-dose interferon-alpha2b in a patient with resected melanoma: a case report and review of the literature. Oncologist. 2012;17(3):384–7.

    Article  PubMed  CAS  Google Scholar 

  56. Powell SF, Dudek AZ. Treatment of melanoma-associated retinopathy. Curr Treat Options Neurol. 2010;12(1):54–63.

    Article  PubMed  Google Scholar 

  57. Jacobzone C, Cochard-Marianowski C, Kupfer I, et al. Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings. Arch Dermatol. 2004;140(10):1258–61.

    Article  PubMed  Google Scholar 

  58. Subhadra C, Dudek AZ, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol. 2008;28(1):23–6.

    Article  PubMed  Google Scholar 

  59. Bianciotto C, Shields CL, Thirkill CE, et al. Paraneoplastic retinopathy with multiple detachments of the neurosensory retina and autoantibodies against interphotoreceptor retinoid binding protein (IRBP) in cutaneous melanoma. Br J Ophthalmol. 2010;94(12):1684–5, 96.

    Article  PubMed  Google Scholar 

  60. Eksandh L, Adamus G, Mosgrove L, Andreasson S. Autoantibodies against bestrophin in a patient with vitelliform paraneoplastic retinopathy and a metastatic choroidal malignant melanoma. Arch Ophthalmol. 2008;126(3):432–5.

    Article  PubMed  CAS  Google Scholar 

  61. Jampol LM, Kim HH, Bryar PJ, et al. Multiple serous retinal detachments and subretinal deposits as the presenting signs of metastatic melanoma. Retina. 2004;24(2):320–2.

    Article  PubMed  Google Scholar 

  62. Nieuwendijk TJ, Hooymans JM. Paraneoplastic vitelliform retinopathy associated with metastatic choroidal melanoma. Eye. 2007;21(11):1436–7.

    Article  PubMed  CAS  Google Scholar 

  63. Sotodeh M, Paridaens D, Keunen J, et al. Paraneoplastic vitelliform retinopathy associated with cutaneous or uveal melanoma and metastases. Klin Monbl Augenheilkd. 2005;222(11):910–4.

    Article  PubMed  CAS  Google Scholar 

  64. Zacks DN, Pinnolis MK, Berson EL, Gragoudas ES. Melanoma-associated retinopathy and recurrent exudative retinal detachments in a patient with choroidal melanoma. Am J Ophthalmol. 2001;132(4):578–81.

    Article  PubMed  CAS  Google Scholar 

  65. Palmowski AM, Haus AH, Pfohler C, et al. Bilateral multifocal chorioretinopathy in a woman with cutaneous malignant melanoma. Arch Ophthalmol. 2002;120(12):1756–61.

    PubMed  Google Scholar 

  66. Adamus G, Karren L. Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy. J Autoimmun. 2009;32(2):133–9.

    Article  PubMed  CAS  Google Scholar 

  67. Wang Y, Abu-Asab MS, Li W, et al. Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy. BMC Ophthalmol. 2012;12:56.

    Article  PubMed  CAS  Google Scholar 

  68. Machemer R. On the pathogenesis of the flat malignant melanoma. Klin Monbl Augenheilkd. 1966;148(5):641–52.

    PubMed  CAS  Google Scholar 

  69. Barr CC, Zimmerman LE, Curtin VT, Font RL. Bilateral diffuse melanocytic uveal tumors associated with systemic malignant neoplasms. A recently recognized syndrome. Arch Ophthalmol. 1982;100(2):249–55.

    Article  PubMed  CAS  Google Scholar 

  70. O’Neal KD, Butnor KJ, Perkinson KR, Proia AD. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. Surv Ophthalmol. 2003;48(6):613–25.

    Article  PubMed  Google Scholar 

  71. Mets RB, Golchet P, Adamus G, et al. Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis. Arch Ophthalmol. 2011;129(9):1235–8.

    Article  PubMed  Google Scholar 

  72. Singh AD, Rundle PA, Slater DN, et al. Uveal and cutaneous involvement in paraneoplastic melanocytic proliferation. Arch Ophthalmol. 2003;121(11):1637–40.

    Article  PubMed  Google Scholar 

  73. Chahud F, Young RH, Remulla JF, et al. Bilateral diffuse uveal melanocytic proliferation associated with extraocular cancers: review of a process particularly associated with gynecologic cancers. Am J Surg Pathol. 2001;25(2):212–8.

    Article  PubMed  CAS  Google Scholar 

  74. Wu S, Slakter JS, Shields JA, Spaide RF. Cancer-associated nummular loss of the pigment epithelium. Am J Ophthalmol. 2005;139(5):933–5.

    Article  PubMed  Google Scholar 

  75. Gass JD, Gieser RG, Wilkinson CP, et al. Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol. 1990;108(4):527–33.

    Article  PubMed  CAS  Google Scholar 

  76. Besirli CG, Comer GM. High-resolution OCT imaging of RPE degeneration in bilateral diffuse uveal melanocytic proliferation. Ophthalmic Surg Lasers Imaging. 2010;41(Suppl):S96–100.

    Article  PubMed  Google Scholar 

  77. Ritland JS, Eide N, Tausjo J. Bilateral diffuse uveal melanocytic proliferation and uterine cancer. A case report. Acta Ophthalmol Scand. 2000;78(3):366–8.

    Article  PubMed  CAS  Google Scholar 

  78. Jaben EA, Pulido JS, Pittock S, et al. The potential role of plasma exchange as a treatment for bilateral diffuse uveal melanocytic proliferation: a report of two cases. J Clin Apher. 2011;26(6):356–61.

    Article  PubMed  Google Scholar 

  79. Ares-Luque A, Garcia-Tunon LA, Saiz A, et al. Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol. 2007;254(8):1131–2.

    Article  PubMed  Google Scholar 

  80. Asproudis IC, Nikas AN, Psilas KG. Paraneoplastic optic neuropathy in a patient with a non-small cell lung carcinoma: a case report. Eur J Ophthalmol. 2005;15(3):420–3.

    PubMed  CAS  Google Scholar 

  81. Carboni G, Forma G, Bond AD, et al. Bilateral paraneoplastic optic neuropathy and unilateral retinal compromise in association with prostate cancer: a differential diagnostic challenge in a patient with unexplained visual loss. Doc Ophthalmol. 2012;125(1):63–70.

    Article  PubMed  Google Scholar 

  82. Srikantha N, Goverdhan S, Evans A. Paraneoplastic optic neuropathy associated with papillary renal cell carcinoma. Br J Ophthalmol. 2011;95(3):429.

    Article  Google Scholar 

  83. Slamovits TL, Posner JB, Reidy DL, et al. Pancreatic neuroendocrine paraneoplastic optic neuropathy: confirmation with antibody to optic nerve and hepatic metastasis. J Neuroophthalmol. 2013;33(1):21–5.

    Article  PubMed  Google Scholar 

  84. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54(12838519):38–50.

    Article  PubMed  Google Scholar 

  85. Calvert PC. A CR(I)MP in the optic nerve: recognition and implications of paraneoplastic optic neuropathy. J Neuroophthalmol. 2006;26(3):165–7.

    Article  PubMed  Google Scholar 

  86. Luiz JE, Lee AG, Keltner JL, et al. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuroophthalmol. 1998;18(3):178–81.

    Article  PubMed  CAS  Google Scholar 

  87. Sheorajpanday R, Slabbynck H, Van De Sompel W, et al. Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. J Neuroophthalmol. 2006;26(3):168–72.

    Article  PubMed  Google Scholar 

  88. Waterston JA, Gilligan BS. Paraneoplastic optic neuritis and external ophthalmoplegia. Aust N Z J Med. 1986;16(5):703–4.

    Article  PubMed  CAS  Google Scholar 

  89. de la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol. 1998;55(3):405–8.

    Article  PubMed  Google Scholar 

  90. Margolin E, Flint A, Trobe JD. High-titer collapsin response-mediating protein-associated (CRMP-5) paraneoplastic optic neuropathy and Vitritis as the only clinical manifestations in a patient with small cell lung carcinoma. J Neuroophthalmol. 2008;28(1):17–22.

    Article  PubMed  Google Scholar 

  91. Digre KB. Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol. 1986;43(11):1165–75.

    Article  PubMed  CAS  Google Scholar 

  92. Wray SH, Dalmau J, Chen A, et al. Paraneoplastic disorders of eye movements. Ann N Y Acad Sci. 2011;1233:279–84.

    Article  PubMed  Google Scholar 

  93. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56(5):715–9.

    Article  PubMed  CAS  Google Scholar 

  94. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29(3):241–51.

    Article  PubMed  CAS  Google Scholar 

  95. Singh AD, Milam AH, Shields CL, et al. Melanoma-associated retinopathy. Am J Ophthalmol. 1995;119:369–70.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmic Oncology, Cole Eye Institute (i32), Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Robert Jack Courtney MD, Rishi P. Singh MD, Mary Beth Aronow MD & Arun D. Singh MD

Authors
  1. Robert Jack Courtney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rishi P. Singh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary Beth Aronow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arun D. Singh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rishi P. Singh MD .

Editor information

Editors and Affiliations

  1. Dept. of Ophthalmic Oncology, Cole Eye Institute Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Arun D. Singh

  2. Ocular Oncology Service, Dept of Ophthalmology, University of California, San Francisco, California, USA

    Bertil Damato

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Courtney, R.J., Singh, R.P., Aronow, M.B., Singh, A.D. (2014). Ocular Paraneoplastic Diseases. In: Singh, A., Damato, B. (eds) Clinical Ophthalmic Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39489-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39489-8_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39488-1

  • Online ISBN: 978-3-642-39489-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation